RE-BVS – Piemonte Repository

Sfoglia per AUTORE
PASSARDI A
Collezione AOU Città della Salute di Torino

Items : 6

Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study. in ESMO open / ESMO Open. 2025 Feb;10(2):104135. doi: 10.1016/j.esmoop.2025.104135. Epub 2025 Feb 4.

2025
AOU Città della Salute di Torino

Antoniotti C; Carullo M; Rossini D; Pietrantonio F; Salvatore L; Lonardi S; Tamberi S; Sciortino C; Conca V; Calegari MA; Ciracì P; Tamburini E; Bergamo F; Boccaccio C; Passardi A; Ritorto G; Ugolini C; Aprile G; Galon J; Cremolini C;

Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2024 Aug 1;42(22):2637-2644. doi: 10.1200/JCO.23.02728. Epub 2024 Jun 12.

2024
AOU Città della Salute di Torino

Antoniotti C; Rossini D; Pietrantonio F; Salvatore L; Lonardi S; Tamberi S; Marmorino F; Moretto R; Prisciandaro M; Tamburini E; Tortora G; Passardi A; Bergamo F; Raimondi A; Ritorto G; Borelli B; Conca V; Ugolini C; Aprile G; Antonuzzo L; Gelsomino F; Martinelli E; Pella N; Masi G; Boni L; Galon J; Cremolini C;

Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. in The Lancet. Oncology / Lancet Oncol. 2022 Jul;23(7):876-887. doi: 10.1016/S1470-2045(22)00274-1. Epub 2022 May 27.

2022
AOU Città della Salute di Torino

Antoniotti C; Rossini D; Pietrantonio F; Catteau A; Salvatore L; Lonardi S; Boquet I; Tamberi S; Marmorino F; Moretto R; Ambrosini M; Tamburini E; Tortora G; Passardi A; Bergamo F; Kassambara A; Sbarrato T; Morano F; Ritorto G; Borelli B; Boccaccino A; Conca V; Giordano M; Ugolini C; Fieschi J; Papadopulos A; Massoué C; Aprile G; Antonuzzo L; et alii...

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. in The Lancet. Oncology / Lancet Oncol. 2020 Apr;21(4):497-507. doi: 10.1016/S1470-2045(19)30862-9. Epub 2020 Mar 9.

2020
AO Cuneo
AOU Città della Salute di Torino

Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Falcone A; Boni L; Zagonel V; Ugolini C; Fontanini G; Corgna E; Cupini S; Mammoliti S; Fenocchio E; Roselli M; Mambrini A; Ritorto G; Di Donato S; Clavarezza M; Carlomagno C; Ronzoni M; Tomasello G; Masi G; Antonuzzo L; Cordio S; Moretto R; Corallo S; Granetto C; Buonadonna A; Zaniboni A; et alii...

Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan. in Clinical colorectal cancer / Clin Colorectal Cancer. 2019 Dec;18(4):e394-e401. doi: 10.1016/j.clcc.2019.08.004. Epub 2019 Sep 4.

2019
ASL Biella
ASL VCO
AO Ordine Mauriziano
AOU Città della Salute di Torino

Lièvre A; Montagnani F; Vasile E; Brac C; Aglietta M; Clerico M; Passardi A; Buscaglia P; Meurisse A; Pasquini G; Neuzillet C; Falcone A; Spadi R; Edeline J; Sperti E; Musettini G; Satolli MA; Vernerey D; De Luca E; Vivaldi C; Lombardi P; Vienot A; Casadei-Gardini A; Leone F; Fornaro L;

Comparing simultaneous integrated boost vs sequential boost in anal cancer patients: results of a retrospective observational study. in Radiation oncology (London, England) / Radiat Oncol. 2018 Sep 10;13(1):172. doi: 10.1186/s13014-018-1124-9.

2018
AOU Città della Salute di Torino

Franco P; De Bari B; Arcadipane F; Lepinoy A; Ceccarelli M; Furfaro G; Mistrangelo M; Cassoni P; Valgiusti M; Passardi A; Casadei Gardini A; Trino E; Martini S; Iorio GC; Evangelista A; Ricardi U; Créhange G; Franco P; De Bari B; Arcadipane F; Lepinoy A; Ceccarelli M; Furfaro G; Mistrangelo M; Cassoni P; Valgiusti M; Passardi A; Casadei Gardini A; Trino E; et alii...